MiroBio
Signal active
Organization
Contact Information
Overview
MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control.
About
Industries
Biotechnology, Life Science
Founded
2019
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
MiroBio headquartered in Europe, operates in the Biotechnology, Life Science sector. The company focuses on Biotechnology and has secured $2.1B in funding across 16 round(s). With a team of 11-50 employees, MiroBio is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - MiroBio, raised $97.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
7
Lead Investors
0
Total Funding Amount
$130.2M
Details
2
MiroBio has raised a total of $130.2M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Early Stage Venture | 33.2M | ||
| 2022 | Early Stage Venture | 97.0M |
Investors
MiroBio is funded by 22 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| SR One | - | FUNDING ROUND - SR One | 97.0M |
| Erez Chimovits | - | FUNDING ROUND - Erez Chimovits | 97.0M |
| MiroBio | - | FUNDING ROUND - MiroBio | 97.0M |
| OrbiMed | - | FUNDING ROUND - OrbiMed | 97.0M |
Recent Activity
There is no recent news or activity for this profile.